Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system.
Flawless balance sheet with limited growth.
Share Price & News
How has Ra Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: P61 has not had significant price volatility in the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: P61 exceeded the German Biotechs industry which returned 10% over the past year.
Return vs Market: P61 exceeded the German Market which returned 12.8% over the past year.
Price Volatility Vs. Market
How volatile is Ra Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Ra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: P61 (€43) is trading above our estimate of fair value (€7.53)
Significantly Below Fair Value: P61 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: P61 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: P61 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate P61's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: P61 is overvalued based on its PB Ratio (7.5x) compared to the DE Biotechs industry average (3.5x).
How is Ra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: P61 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: P61 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: P61 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: P61's revenue (69.4% per year) is forecast to grow faster than the German market (5.2% per year).
High Growth Revenue: P61's revenue (69.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: P61 is forecast to be unprofitable in 3 years.
How has Ra Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: P61 is currently unprofitable.
Growing Profit Margin: P61 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: P61 is unprofitable, and losses have increased over the past 5 years at a rate of -39.6% per year.
Accelerating Growth: Unable to compare P61's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: P61 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).
Return on Equity
High ROE: P61 has a negative Return on Equity (-27.95%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Ra Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: P61's short term assets ($300.2M) exceed its short term liabilities ($11.7M).
Long Term Liabilities: P61's short term assets ($300.2M) exceed its long term liabilities ($3.5M).
Debt to Equity History and Analysis
Debt Level: P61 is debt free.
Reducing Debt: P61 has not had any debt for past 5 years.
Inventory Level: P61 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if P61's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: P61 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: P61 has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of -36.5% each year.
What is Ra Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate P61's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate P61's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if P61's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if P61's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of P61's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Treco (61yo)
Dr. Douglas A. Treco, also known as Doug, Ph.D. co-founded Ra Pharmaceuticals, Inc., and has been its President also Chief Executive Officer since June 2008. He is Entrepreneur-in-Residence at Lightstone V ...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD1.98M) is above average for companies of similar size in the German market ($USD1.52M).
Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.
|Executive VP||4.1yrs||US$1.13m||0.017% $349.8k|
|Chief Medical Officer||3.6yrs||US$1.15m||0.015% $306.6k|
|Chief Technology & Innovation Officer and Head of Research||0.9yrs||no data||0.0049% $98.3k|
|Chief Scientific Officer||3.8yrs||US$841.75k||0.013% $267.9k|
|Chief Commercial Officer||1.8yrs||no data||0.023% $465.3k|
|Senior Vice President of Regulatory||1.3yrs||no data||no data|
|Senior Vice President of Technical Operations||0.6yrs||no data||no data|
|Vice President of Operations||0yrs||no data||no data|
Experienced Management: P61's management team is considered experienced (2.7 years average tenure).
|Independent Director||3.8yrs||US$152.93k||0.11% $2.3m|
|Independent Chairman of the Board||10yrs||US$165.43k||0.064% $1.3m|
|Independent Director||3.9yrs||US$137.93k||0.11% $2.3m|
|Independent Director||4.6yrs||US$145.43k||0.064% $1.3m|
|Chairman of Scientific Advisory Board||0yrs||no data||no data|
|Member of Scientific Advisory Board||0yrs||no data||no data|
|Independent Director||1.4yrs||US$289.96k||0.018% $358.1k|
|Independent Director||1.3yrs||US$228.37k||no data|
Experienced Board: P61's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.5%.
Ra Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ra Pharmaceuticals, Inc.
- Ticker: P61
- Exchange: DB
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$2.201b
- Listing Market Cap: US$2.026b
- Shares outstanding: 47.15m
- Website: https://rapharma.com
Number of Employees
- Ra Pharmaceuticals, Inc.
- 87 Cambridge Park Drive
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RARX||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Oct 2016|
|P61||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 2016|
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company’s peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is Zilucoplan, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of generalized myasthenia gravis (gMG); has completed Phase II clinical trial for treating paroxysmal nocturnal hemoglobinuria (PNH); and has completed Phase Ib clinical trial to treat patients with renal impairment. The company’s pre-clinical programs include Factor D inhibition for treating C3 glomerulonephritis and dense deposit disease; and inhibitors of other complement factors for renal, autoimmune, and central nervous system diseases. It has collaboration and license agreement with Merck & Co., Inc. to identify orally available cyclic peptides for non-complement program targets, and provide research and development services. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/23 22:35|
|End of Day Share Price||2020/02/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.